Partial
Mostly Aligned
Patient Risk:
Low
Summary
The identity/mechanism claims for AJOVY/fremanezumab are supported by the provided label section (Description). Historical launch date and Teva/sponsor association claims are not supported by the supplied FDA label excerpts, and no dosing/safety labeling elements were available to evaluate.
Category Scores
Accurate Statements
Fremanezumab is a CGRP monoclonal antibody.
Supported by 11 DESCRIPTION, which states AJOVY (fremanezumab-vfrm) is a monoclonal antibody specific for calcitonin gene-related peptide (CGRP) ligand.
Unsupported Statements
Ajovy is a brand of fremanezumab.
Only partially supported: 11 DESCRIPTION refers to AJOVY (fremanezumab-vfrm), but the claim does not match the label’s US proper name format/suffix ("-vfrm").
Ajovy was first launched in the United States in 2018.
Not supported by any of the provided label sections (no launch date or marketing history is included).
Teva is associated with a fremanezumab product label/listing in the U.S.
Not supported by the provided label sections (no Teva/sponsor/labeler identity information included).
The product’s first U.S. launch date for fremanezumab itself is 2018.
Not supported by any provided label sections (no launch date information included).
Contradictions
Important Omissions
No evaluation possible for contraindications, boxed warnings, dosing/administration, drug interactions, adverse reactions, monitoring, or specific populations because those label sections were not provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only label-supported claims concern product identity/mechanism. The unsupported claims relate to launch timing and sponsor association, which are not directly dosing/safety statements based on the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Historical launch date and Teva association claims are not supported by the provided FDA label sections.
Suggested Improvement
Limit claims to what is present in the provided label excerpts (e.g., identity and CGRP monoclonal antibody description) and remove/verify external timeline or sponsor/labeler assertions using supported label text.